ES2593618T3 - Composición oral tópica para aliviar los síntomas de la boca seca y para el tratamiento de úlceras bucales - Google Patents
Composición oral tópica para aliviar los síntomas de la boca seca y para el tratamiento de úlceras bucales Download PDFInfo
- Publication number
- ES2593618T3 ES2593618T3 ES12197696.3T ES12197696T ES2593618T3 ES 2593618 T3 ES2593618 T3 ES 2593618T3 ES 12197696 T ES12197696 T ES 12197696T ES 2593618 T3 ES2593618 T3 ES 2593618T3
- Authority
- ES
- Spain
- Prior art keywords
- oral composition
- topical oral
- topical
- composition according
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000000699 topical effect Effects 0.000 title claims abstract description 26
- 206010013781 dry mouth Diseases 0.000 title claims description 16
- 238000011282 treatment Methods 0.000 title claims description 6
- 208000024891 symptom Diseases 0.000 title claims description 5
- 208000002399 aphthous stomatitis Diseases 0.000 title description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229960003080 taurine Drugs 0.000 claims abstract description 15
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims abstract description 14
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000811 xylitol Substances 0.000 claims abstract description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 9
- 229960002675 xylitol Drugs 0.000 claims abstract description 9
- 235000010447 xylitol Nutrition 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- -1 fluoride anions Chemical class 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 230000000395 remineralizing effect Effects 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 6
- 229960004711 sodium monofluorophosphate Drugs 0.000 claims description 6
- 208000007117 Oral Ulcer Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 229940091249 fluoride supplement Drugs 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000002324 mouth wash Substances 0.000 claims description 4
- 230000001033 osmoprotective effect Effects 0.000 claims description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 4
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 229940112822 chewing gum Drugs 0.000 claims description 3
- 229940051866 mouthwash Drugs 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011775 sodium fluoride Substances 0.000 claims description 3
- 235000013024 sodium fluoride Nutrition 0.000 claims description 3
- 229960000414 sodium fluoride Drugs 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 229940034610 toothpaste Drugs 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 229960003563 calcium carbonate Drugs 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 229960002079 calcium pantothenate Drugs 0.000 claims description 2
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 2
- KMXTYZBQPJXGNK-UHFFFAOYSA-N hexadecan-1-amine;hydron;fluoride Chemical compound F.CCCCCCCCCCCCCCCCN KMXTYZBQPJXGNK-UHFFFAOYSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 239000011698 potassium fluoride Substances 0.000 claims description 2
- 235000003270 potassium fluoride Nutrition 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 claims description 2
- 235000015870 tripotassium citrate Nutrition 0.000 claims description 2
- LRHDEXKRLAKMOP-UHFFFAOYSA-N 3-[3-aminopropyl(2-hydroxyethyl)amino]-3-heptadecylpentane-1,5-diol;dihydrofluoride Chemical compound F.F.CCCCCCCCCCCCCCCCCC(CCO)(CCO)N(CCO)CCCN LRHDEXKRLAKMOP-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 4
- 244000228451 Stevia rebaudiana Species 0.000 description 4
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 4
- 239000004227 calcium gluconate Substances 0.000 description 4
- 235000013927 calcium gluconate Nutrition 0.000 description 4
- 229960004494 calcium gluconate Drugs 0.000 description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 4
- 235000012209 glucono delta-lactone Nutrition 0.000 description 4
- 229960003681 gluconolactone Drugs 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 229960003885 sodium benzoate Drugs 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 210000001779 taste bud Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- PGYUUZGTXNCKJF-UHFFFAOYSA-N 3-[3-aminopropyl(2-hydroxyethyl)amino]-3-heptadecylpentane-1,5-diol Chemical compound CCCCCCCCCCCCCCCCCC(CCO)(CCO)N(CCO)CCCN PGYUUZGTXNCKJF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229950004297 lauril Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000018962 mouth sore Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000426 osmoregulatory effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 235000019669 taste disorders Nutrition 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composición tópica oral que comprende taurina o una sal de esta, xilitol y propano-1,3-diol.
Description
5
10
15
20
25
30
35
40
45
50
55
60
DESCRIPCION
Composicion oral topica para aliviar los slntomas de la boca seca y para el tratamiento de ulceras bucales
La invencion se refiere a una composicion oral topica que comprende taurina, propandiol y xilitol y su uso para aliviar o eliminar los slntomas de la boca seca y/o prevenir o tratar de ulceras de la boca.
La boca seca o xerostomia es causada por una disminucion en la actividad de las glandulas salivales. La reduccion del flujo salival puede dar lugar a malestar, interferir con el habla y la deglucion, dificultar el uso de dentadura postiza, causar halitosis, y poner en peligro la higiene bucal causando una disminucion en el pH oral y un aumento en el crecimiento bacteriano. La sequedad es una queja comun entre los adultos mayores, que afecta a alrededor del 20 % de las personas mayores.
Las causas de la boca seca son diferentes e implican muchos factores como el estres, la infeccion de las glandulas salivales o el uso de farmacos como los anticolinergicos, antiparkinsonianos, antineoplasicos, la radiacion en la cabeza y el cuello (para el tratamiento del cancer) o pueden estar tambien asociadas a ciertas enfermedades como el slndrome de Sjogren y el VIH/SIDA, la diabetes no controlada, y otros trastornos.
La boca seca se trata actualmente con enjuagues bucales, aplicaciones topicas, sustitutos salivales, o estimulantes salivales, tales como caramelos sin azucar y goma de mascar. Algunos estimulantes de la saliva estan disponibles comercialmente. Los tratamientos actuales se centran en aliviar los slntomas y prevenir las caries dentales. Los productos de saliva artificial a menudo son el tratamiento de eleccion para los pacientes con xerostomia.
La boca seca puede hacer que los tejidos blandos de la boca, como la membrana mucosa oral, tejido gingival y las papilas gustativas de la lengua sean mas vulnerables a los danos fisicos, fisicoquimicos y biologicos. Sin embargo, los tratamientos / productos existentes no resuelven el problema de la dificultad de los tejidos blandos. Las presentes composiciones resuelven este problema debido al efecto de proteccion y la promocion de reparacion de los tejidos blandos orales.
Las ulceras y las lesiones bucales son formas inflamatorias que se producen en la mucosa oral con lesiones eritematosas similares a las quemaduras y lesiones, tales ulceras dolorosas hacen que sea dificil masticar y tragar, poniendo en peligro la calidad de vida del paciente. Son dolorosas debido a la eliminacion de una capa de la mucosa oral, expoiendo las terminaciones nerviosas por debajo.
Existe un numero de diversas causas, incluyendo aparatos y protesis de mala colocacion, trauma fisico o quimico, boca seca, la toma de medicamentos inmunosupresores, quemaduras, alergias, infeccion causada por microorganismos o virus. Una vez formada, la ulcera puede ser mantenida por la inflamacion y/o infeccion secundaria. Dos tipos de ulceras orales comunes son las aftas (llagas bucales) y el herpes labial. El herpes labial puede ser causado por el virus del herpes simple.
Las ulceras bucales son manejadas con enjuagues topicos, geles topicos y liquidos, modificaciones del comportamiento, analgesicos y medidas preventivas.
De acuerdo con la presente invencion, se ha encontrado que las composiciones que contienen taurina, xilitol y propano- 1,3-diol, por via topica aplicadas a la membrana mucosa de la boca, ejercen efectos beneficiosos sobre la boca seca y promueven la regeneracion de la membrana mucosa oral.
La presente invencion proporciona composiciones orales topicas que comprenden taurina o una sal de esta, xilitol y propano-1,3-diol.
La taurina (acido 2-aminoetanosulfonico) es un acido organico ampliamente distribuido en los tejidos animales. La taurina esta presente en alta concentracion en el plasma y celulas de mamiferos y juega un papel importante en un numero de procesos biologicos. La taurina ha demostrado tener actividad osmoregulatoria, antioxidante, antiapoptotica, antiinflamatoria y antilipidica.
El xilitol se clasifica como un poliol y se considera un edulcorante "sin azucar". El xilitol se conoce por reducir el riesgo de caries dentales.
El propano-1,3-diol se comercializa bajo la marca comercial Zemea® y es conocido por ser un modificador de sensorial, humectante, emoliente o disolvente.
La composicion de la presente invencion es capaz de proteger los tejidos blandos de la boca y promover su reparacion, para aliviar la inflamacion de los tejidos blandos de la boca, para evitar trastornos del gusto debido a la proteccion de las papilas gustativas y para proteger de danos sequedad debido a la funcion humectante.
5
10
15
20
25
30
35
40
45
50
55
60
65
La concentracion de taurina en la composicion varla de 0,01 a 5,0 % en peso, preferentemente, la concentracion es de 0,1 a 1,0 % en peso.
La concentracion de xilitol en la composicion varla desde 0,1 hasta 10,0 % en peso, preferentemente, la concentracion es de 0,5 a 5,0 % en peso.
La concentracion de propano-1,3-diol en la composicion varla desde 0,1 hasta 30,0 % en peso, preferentemente, la concentracion es de 2,0 a 20,0 % en peso.
La composicion puede comprender, ademas, hialuronato de sodio.
El hialuronato de sodio esta presente en una concentracion de 0,01 a 1,0 % en peso, preferentemente la concentracion es de 0,05 a 0,3% en peso. El hialuronato de sodio tiene preferentemente un peso molecular (MW) de 1,0 a 1,5 x 106.
Las composiciones de la invencion pueden comprender otros componentes tales como agentes remineralizantes, agentes osmoprotectores, agentes lubricantes, compuestos para estimular el flujo de saliva.
Los agentes remineralizantes se eligen preferentemente entre los aniones fluoruro, aniones fosfato, cationes de sodio y cationes de potasio tales como fluoruro de potasio, fluoruro de sodio, monofluorofosfato de sodio, fluoruro de estano, fluoruros de amina (hidrofluoruro hexadecilamina, bis- (hidroxietil)aminopropil-N-hidroxietil-octadecilamina
dihidrofluoruro, N-N', N'-tri(polioxietileno)-N-hexadecil-propilendiamina dihidrofluoruro o hidrofluoruro de
octadecenilamina), fosfato de potasio, pirofosfato de potasio, citrato tripotasico, lactato de calcio, pantotenato de calcio y carbonato de calcio.
El agente remineralizante preferido es monofluorofosfato de sodio que esta presente preferentemente en concentraciones de 0,10 a 1,14 % en peso.
El agente osmoprotector es preferentemente betalna, que esta presente preferentemente en concentraciones de 0,5 a
5.0 % en peso.
El agente lubricante preferido es polivinilpirrolidona, que es preferentemente esta presente en concentraciones de 0,01 a
5.0 % en peso.
El compuesto para estimular el flujo de saliva puede ser una sal de citrato o acido cltrico. El compuesto preferido para estimular el flujo de saliva es el citrato de sodio/acido cltrico que esta presente preferentemente en concentraciones de 0,5 a 5,0 % en peso. La composicion de la invencion puede incluir en cada tiempo todos los ingredientes necesarios conocidos para el experto en la tecnica para obtener las propiedades organolepticas y reologicas necesarias.
La composicion oral topica segun las reivindicaciones puede estar en forma de gel, aerosol, crema dental, enjuague bucal, parche oral, goma de mascar y tabletas.
EJEMPLOS
Ejemplo 1
- Gel para la sequedad en la boca
- Nombres INCI-UE
- %
- AQUA
- 49,583969
- SORBITOL, AQUA
- 25,000000
- PROPANODIOL
- 15,000000
- PVP
- 3,000000
- CITRATO DE SODIO
- 2,400000
- BETAINA
- 1,000000
- GLUCONOLACTONA, BENZOATO DE SODIO, GLUCONATO DE CALCIO
- 1,000000
- CARRAGENINA
- 0,700000
5
10
15
20
25
30
35
40
45
50
55
60
65
- GOMA XANTANA
- 0,700000
- XILITOL
- 0,500000
- ACEITE DE RICINO HIDROGENADO PEG-40
- 0,400000
- TAURINA
- 0,300000
- Acido citrico
- 0,240000
- HIDROXIDO DE SODIO
- 0,076000
- HIALURONATO DE SODIO
- 0,050000
- SUCRALOSA
- 0,030000
- EXTRACTO DE STEVIA REBAUDIANA
- 0,010000
- CI 19140
- 0,000026
- CI42090
- 0,000005
- total
- 100,000000
Ejemplo 2
- Pasta de dientes boca seca
- Nombres INCI-UE
- %
- SORBITOL, AGUA
- 43,000000
- AQUA
- 15,843000
- PROPANODIOL
- 10,000000
- SILICE
- 13,500000
- BETAINA
- 4,000000
- LAURIL GLUCOSIDO
- 3,000000
- COCAMIDOPROPIL BETAINA, AQUA
- 2,000000
- GOMA XANTANA
- 1,500000
- POLISORBATO 20
- 1,500000
- CITRATO DE SODIO
- 1,200000
- MONOFLUOROFOSFATO DE SODIO
- 1,097000
- XILITOL
- 1,000000
- GLUCONOLACTONA, BENZOATO DE SODIO, GLUCONATO DE CALCIO
- 0,800000
- AROMA
- 0,500000
- CI77891
- 0,400000
- TAURINA
- 0,300000
- EXTRACTO DE STEVIA REBAUDIANA
- 0,100000
- SUCRALOSA
- 0,100000
- Acido citrico
- 0,100000
- HIALURONATO DE SODIO
- 0,050000
- PVP
- 0,010000
- total
- 100,000000
5
10
15
20
25
30
35
40
45
50
55
60
65
Ejemplo 3
- Enjuague bucal para boca seca
- Nombres INCI-UE
- %
- AQUA
- 79,480000
- SORBITOL, AQUA
- 10,000000
- CITRATO DE SODIO
- 2,400000
- PVP
- 2,000000
- PROPANODIOL
- 2,000000
- BETAINA
- 1,000000
- GLUCONOLACTONA, BENZOATO DE SODIO, GLUCONATO DE CALCIO
- 1,000000
- ACEITE DE DE RICINO HIDROGENADO PEG-40
- 0,600000
- XILITOL
- 0,500000
- TAURINA
- 0,300000
- Acido citrico
- 0,240000
- MONOFLUOROFOSFATO DE SODIO
- 0,190000
- HIDROXIDO DE SODIO
- 0,100000
- AROMA
- 0,090000
- HIALURONATO DE SODIO
- 0,050000
- HIDROXIETILCELULOSA
- 0,020000
- SUCRALOSA
- 0,020000
- EXTRACTO DE STEVIA REBAUDIANA
- 0,010000
- total
- 100,000000
Ejemplo 4
- Aerosol para boca seca
- Nombres INCI-UE
- %
- AQUA
- 79,560000
- SORBITOL, AQUA
- 10,000000
- CITRATO DE SODIO
- 2,300000
- PVP
- 2,000000
- PROPANODIOL
- 2,000000
- BETAINA
- 1,000000
- GLUCONOLACTONA, BENZOATO DE SODIO, GLUCONATO DE CALCIO
- 1,000000
- ACEITE DE DE RICINO HIDROGENADO PEG-40
- 1,000000
- XILITOL
- 0,500000
- TAURINA
- 0,300000
- Acido citrico
- 0,240000
- HIALURONATO DE SODIO
- 0,050000
5
10
15
20
25
30
35
40
45
50
55
60
65
EXTRACTO DE STEVIA REBAUDIANA
AROMA
total
0,010000
0,010000
100,000000
Claims (17)
- 510152025303540455055Reivindicaciones1. Una composition topica oral que comprende taurina o una sal de esta, xilitol y propano-1,3-diol.
- 2. La composicion oral topica de la reivindicacion 1 en donde la concentration de taurina o una sal de esta es de 0,01 a 5,0 % en peso.
- 3. La composicion oral topica de la reivindicacion 1 o 2 en donde la concentracion de xilitol es de 0,1 a 10,0 % en peso.
- 4. La composicion oral topica de acuerdo con cualquiera de las reivindicaciones 1-3 en donde la concentracion de propano-1,3-diol es de 0,1 a 30,0 % en peso.
- 5. La composicion oral topica de acuerdo con una cualquiera de las reivindicaciones 1-4, que comprende ademas hialuronato de sodio.
- 6. La composicion oral topica de acuerdo con una cualquiera de las reivindicaciones 1-5, que comprende ademas un agente remineralizante.
- 7. La composicion oral topica de la reivindicacion 6 en donde el agente remineralizante se selecciona del grupo que consiste en aniones fluoruro, aniones fosfato, cationes de sodio y cationes de potasio tales como fluoruro de potasio, fluoruro de sodio, monofluorofosfato de sodio, fluoruro de estano, fluoruros de amina (hexadecilamina hidrofluoruro, bis-(hidroxietil) aminopropil-N-hidroxietil-octadecilamina dihidrofluoruro, N-N',N'- tri (polioxietileno)-N-hexadecil-propilendiamina dihidrofluoruro o hidrofluoruro octadecenilamina), fosfato de potasio, pirofosfato de potasio, citrato tripotasico, lactato de calcio, pantotenato de calcio y carbonato de calcio.
- 8. La composicion oral topica de la reivindicacion 7 en donde el agente remineralizante es monofluorofosfato de sodio o fluoruro de sodio.
- 9. La composicion oral topica de acuerdo con una cualquiera de las reivindicaciones 1-8, que comprende ademas un agente osmoprotector.
- 10. La composicion oral topica de la reivindicacion 9 en donde el agente osmoprotector es betalna.
- 11. La composicion oral topica de acuerdo con cualquiera de las reivindicaciones 1-10, que comprende ademas un agente lubricante.
- 12. La composicion oral topica de acuerdo con la reivindicacion 11 en donde el agente lubricante es polivinilpirrolidona.
- 13. La composicion oral topica de las reivindicaciones 1-12 que comprende ademas un compuesto para estimular el flujo de saliva.
- 14. La composicion oral topica de la reivindicacion 13 en donde el compuesto para estimular el flujo de saliva es una sal de citrato o acido cltrico.
- 15. La composicion oral topica de acuerdo con cualquiera de las reivindicaciones 1-14, en forma de gel, aerosol, pasta de dientes, enjuague bucal, parche oral, goma de mascar y tabletas.
- 16. La composicion oral topica de acuerdo con cualquiera de las reivindicaciones 1-15 para aliviar o eliminar los slntomas de la boca seca.
- 17. La composicion oral topica de acuerdo con cualquiera de las reivindicaciones 1-15 para la prevention o el tratamiento de las ulceras bucales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12197696.3A EP2745836B1 (en) | 2012-12-18 | 2012-12-18 | Topical oral composition for alleviating dry mouth symptoms and for treating mouth ulcers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2593618T3 true ES2593618T3 (es) | 2016-12-12 |
Family
ID=47427251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12197696.3T Active ES2593618T3 (es) | 2012-12-18 | 2012-12-18 | Composición oral tópica para aliviar los síntomas de la boca seca y para el tratamiento de úlceras bucales |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9895326B2 (es) |
| EP (1) | EP2745836B1 (es) |
| JP (1) | JP6461002B2 (es) |
| CN (1) | CN104955447B (es) |
| CA (1) | CA2895249C (es) |
| ES (1) | ES2593618T3 (es) |
| WO (1) | WO2014095489A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2971708A1 (en) * | 2014-12-23 | 2016-06-30 | Colgate-Palmolive Company | Oral care composition |
| WO2016153015A1 (ja) * | 2015-03-25 | 2016-09-29 | 株式会社ファルマクリエ神戸 | 高分子薬効成分を含有した口腔内施用物および口腔内への高分子薬効成分の投与方法 |
| CN105833278B (zh) * | 2016-04-25 | 2018-05-08 | 北京嘉安医疗器械科技有限公司 | 用于治疗口腔干燥和口腔疾病的组合物 |
| JP7455317B2 (ja) * | 2017-06-30 | 2024-03-26 | 小林製薬株式会社 | 口腔用組成物 |
| US10245236B1 (en) * | 2018-01-12 | 2019-04-02 | Lisa Carroll | Method and product for treating mouth-related disorders |
| US12083209B2 (en) | 2020-02-18 | 2024-09-10 | Sunstar Americas, Inc. | Oral care composition |
| WO2022159860A1 (en) * | 2021-01-25 | 2022-07-28 | Colgate-Palmolive Company | Solid oral care compositions comprising pvp and hec as binder system |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63132820A (ja) * | 1986-11-22 | 1988-06-04 | Minoru Nakano | 口腔用組成物 |
| US4997654A (en) * | 1989-08-14 | 1991-03-05 | Warner-Lambert Company | Method for increasing salivation for xerostomia patients |
| BR9607778A (pt) * | 1995-03-28 | 1998-07-07 | Novo Nordisk As | Composição para cuidados da cavidade oral contendo uma protease produto para cuidados da cavidade oral uso e processo para utilizar produtos para cuidados da cavidade oral |
| AU724729B2 (en) * | 1995-08-18 | 2000-09-28 | Colgate-Palmolive Company | Tooth bleaching |
| JPH11130644A (ja) * | 1997-10-29 | 1999-05-18 | Lion Corp | 口腔用組成物 |
| WO2000056344A1 (fr) * | 1999-03-24 | 2000-09-28 | Seikagaku Corporation | Salive artificielle |
| EP1242113A2 (en) * | 1999-12-30 | 2002-09-25 | University Of Louisville Research Foundation, Inc. | Methods and compositions for inhibiting adhesion by microorganisms |
| FI114538B (fi) * | 2001-01-12 | 2004-11-15 | Finnfeeds Finland Ltd | Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen |
| ES2186569B1 (es) * | 2001-09-28 | 2004-09-16 | Lacer, S.A. | Composiciones para el alivio de la xerostomia y el tratamiento de los trastornos asociados con la misma. |
| US8168161B2 (en) * | 2004-12-22 | 2012-05-01 | Hill's Pet Nutrition, Inc. | Method to promote oral health in companion animals |
| AR052840A1 (es) * | 2004-12-22 | 2007-04-04 | Colgate Palmolive Co | Composiciones para el cuidado oral que contienen flavonoides y flavanos |
| US20060140881A1 (en) * | 2004-12-22 | 2006-06-29 | Guofeng Xu | Oral care compositions containing flavonoids and flavans |
| JP5258756B2 (ja) * | 2006-05-17 | 2013-08-07 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | パーソナルケア組成物 |
| EP2127646B1 (en) * | 2007-01-31 | 2012-08-01 | Kaneka Corporation | Agent for relief or prevention of xerostomia |
| ES2304103B1 (es) * | 2007-02-22 | 2009-08-07 | Biocosmetics S.L. | Composicion para tratamiento de la xerostomia o boca seca. |
| US20090104128A1 (en) * | 2007-10-17 | 2009-04-23 | Orahealth Corporation | Denture adhesive compositions with anti-ucler agents |
| US20100022471A1 (en) * | 2008-07-23 | 2010-01-28 | Sage Products Inc. | Oral Moisturizer for Alleviating Dry Mouth |
| PL2418945T3 (pl) * | 2009-04-15 | 2019-05-31 | Bmg Pharma S P A | Kompozycje soli mineralnej - kwasu sulfonowego i sposoby ich stosowania |
| CN101810336B (zh) * | 2010-04-30 | 2012-03-21 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
| JP5756614B2 (ja) * | 2010-11-02 | 2015-07-29 | 花王株式会社 | オートインデューサー−2阻害剤、並びに齲蝕病の予防及び/又は治療剤 |
| JP5730041B2 (ja) * | 2011-01-28 | 2015-06-03 | 日本ゼトック株式会社 | 口腔用組成物 |
| AU2012256033B2 (en) * | 2011-05-16 | 2015-07-02 | Colgate-Palmolive Company | Oral care composition for treating dry mouth |
-
2012
- 2012-12-18 EP EP12197696.3A patent/EP2745836B1/en active Active
- 2012-12-18 ES ES12197696.3T patent/ES2593618T3/es active Active
-
2013
- 2013-12-10 CA CA2895249A patent/CA2895249C/en active Active
- 2013-12-10 JP JP2015546975A patent/JP6461002B2/ja active Active
- 2013-12-10 WO PCT/EP2013/076080 patent/WO2014095489A1/en not_active Ceased
- 2013-12-10 CN CN201380065761.9A patent/CN104955447B/zh active Active
- 2013-12-10 US US14/652,126 patent/US9895326B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2895249A1 (en) | 2014-06-26 |
| EP2745836B1 (en) | 2016-08-31 |
| JP2016510308A (ja) | 2016-04-07 |
| EP2745836A1 (en) | 2014-06-25 |
| CN104955447A (zh) | 2015-09-30 |
| CN104955447B (zh) | 2019-02-22 |
| WO2014095489A1 (en) | 2014-06-26 |
| CA2895249C (en) | 2021-06-22 |
| US9895326B2 (en) | 2018-02-20 |
| US20150320701A1 (en) | 2015-11-12 |
| JP6461002B2 (ja) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2593618T3 (es) | Composición oral tópica para aliviar los síntomas de la boca seca y para el tratamiento de úlceras bucales | |
| ES2632363T3 (es) | Composición farmacéutica antiséptica para la higiene bucal y el tratamiento de enfermedades bucales de origen microbiano | |
| JP2927850B2 (ja) | 歯とその支持組織の症状の治療のための局所用製剤 | |
| CN110996891B (zh) | 包含氯己定的凝胶 | |
| AR029542A1 (es) | Composiciones para el cuidado bucal que contienen clorito y sus metodos | |
| Al Habashneh et al. | The effect of a triclosan/copolymer/fluoride toothpaste on plaque formation, gingivitis, and dentin hypersensitivity: A single-blinded randomized clinical study | |
| ES2385236A1 (es) | Composición y método para reducir la desmineralización de los dientes. | |
| KR101268338B1 (ko) | 바다제비집 추출물을 유효성분으로 포함하는 구강위생 증진용 조성물 | |
| ES2989135T3 (es) | Formulación para el cuidado bucal y método para la eliminación del sarro y la placa de los dientes | |
| CN108042420B (zh) | 一种用于口腔保健的组合物及其应用 | |
| RU2550957C1 (ru) | Способ лечения хронического генерализованного пародонтита | |
| CZ308891B6 (cs) | Aplikační směs pro zvýšení účinnosti antiseptik a/nebo dezinficiens, aplikační prostředek obsahující aplikační směs, a použití této směsi | |
| KR102700606B1 (ko) | 이카리틴을 포함하는 구강질환 예방 또는 치료용 조성물 | |
| WO2004073702A1 (es) | Composicion para el tratamiento de la cavidad bucal y utilizaciones correspondientes | |
| KR20160061852A (ko) | 금속이온 봉쇄제와 이소프로필메틸페놀을 함유하는 구강 조성물 | |
| KR20170051006A (ko) | 이소프로필메틸페놀과 구강조직수렴제를 함유하는 구강 조성물 | |
| KR102769827B1 (ko) | 네페린을 포함하는 구강질환 예방 또는 치료용 조성물 | |
| RU2813879C1 (ru) | Противовоспалительная композиция (варианты) для местного применения в полости рта и верхних дыхательных путях | |
| KR102657495B1 (ko) | 아스틸빈(Astilbin)을 포함하는 구강질환 예방 또는 치료용 조성물 | |
| KR102726894B1 (ko) | 스쿠텔라레인을 포함하는 구강질환 예방 또는 치료용 조성물 | |
| KR102700607B1 (ko) | 틸리로사이드를 포함하는 구강질환 예방 또는 치료용 조성물 | |
| KR102626865B1 (ko) | 크로토노시드(Crotonoside)를 포함하는 구강질환 예방 또는 치료용 조성물 | |
| KR102782163B1 (ko) | 푸니칼라진을 포함하는 구강질환 예방 또는 치료용 조성물 | |
| CN107106446A (zh) | 口腔护理组合物 | |
| KR102769828B1 (ko) | 살비아논산 비를 포함하는 구강질환 예방 또는 치료용 조성물 |